PURPOSE: To explore the feasibility of a short course of hypofractionated conformal radiation therapy to the tumor bed as part of a breast preservation protocol in postmenopausal patients with nonpalpable pT1N0 stage breast cancer. MATERIALS AND METHODS: The tumor bed was imaged at computed tomography (CT) in the prone position on a dedicated table. The same table and position were used for treatment with a 4-MV linear accelerator. The planning target volume was the tumor bed plus a 1-2-cm margin defined at postmastectomy CT. A regimen of five fractions was tested in this pilot dose study. Cosmesis was assessed by patients and physicians before treatment and 36 months after treatment. RESULTS: Ten consecutive patients who were eligible for the study were assigned to one of three dose-per-fraction regimens; nine were treatable with the proposed technique on the basis of CT findings. Patients received five fractions over 10 days (total dose range, 25-30 Gy): Three received 5.0 Gy per fraction; four, 5.5 Gy; and two, 6.0 Gy. At minimum follow-up of 36 months (range, 36-53 months), all patients were alive and disease free with good to excellent cosmesis. CONCLUSION: Hypofractionated conformal breast radiation therapy is feasible. Further studies are warranted.
PURPOSE: To explore the feasibility of a short course of hypofractionated conformal radiation therapy to the tumor bed as part of a breast preservation protocol in postmenopausal patients with nonpalpable pT1N0 stage breast cancer. MATERIALS AND METHODS: The tumor bed was imaged at computed tomography (CT) in the prone position on a dedicated table. The same table and position were used for treatment with a 4-MV linear accelerator. The planning target volume was the tumor bed plus a 1-2-cm margin defined at postmastectomy CT. A regimen of five fractions was tested in this pilot dose study. Cosmesis was assessed by patients and physicians before treatment and 36 months after treatment. RESULTS: Ten consecutive patients who were eligible for the study were assigned to one of three dose-per-fraction regimens; nine were treatable with the proposed technique on the basis of CT findings. Patients received five fractions over 10 days (total dose range, 25-30 Gy): Three received 5.0 Gy per fraction; four, 5.5 Gy; and two, 6.0 Gy. At minimum follow-up of 36 months (range, 36-53 months), all patients were alive and disease free with good to excellent cosmesis. CONCLUSION: Hypofractionated conformal breast radiation therapy is feasible. Further studies are warranted.
Authors: Silvia C Formenti; Howard Hsu; Maria Fenton-Kerimian; Daniel Roses; Amber Guth; Gabor Jozsef; Judith D Goldberg; J Keith Dewyngaert Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-09 Impact factor: 7.038
Authors: Henry M Kuerer; Thomas B Julian; Eric A Strom; H Kim Lyerly; Armando E Giuliano; Eleftherios P Mamounas; Frank A Vicini Journal: Ann Surg Date: 2004-03 Impact factor: 12.969
Authors: Reshma Jagsi; Merav A Ben-David; Jean M Moran; Robin B Marsh; Kent A Griffith; James A Hayman; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038
Authors: Frank Vicini; Kathryn Winter; John Wong; Helen Pass; Rachel Rabinovitch; Susan Chafe; Douglas Arthur; Ivy Petersen; Julia White; Beryl McCormick Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-10 Impact factor: 7.038
Authors: Brigid E Hickey; Melissa L James; Margot Lehman; Phil N Hider; Mark Jeffery; Daniel P Francis; Adrienne M See Journal: Cochrane Database Syst Rev Date: 2016-07-18